A 1000 ng/mL D-dimer threshold safely rules out pulmonary embolism in low-likelihood patients, reducing unnecessary chest imaging in emergency care.

Having had a front seat view to the struggles faced by patients suffering from poor circulation, two young medical doctors have partnered to make compression therapy more affordable and accessible to ...

Dublin, Dec. 19, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Embolism Market - A Global and Regional Analysis, 2025-2035" has been added to ResearchAndMarkets.com's offering. The global pulmonary embolism ...

Boston Scientific has agreed to acquire Penumbra in a deal worth about $14.5 billion. Boston Scientific has agreed to acquire ...

Supported by the Israel Innovation Authority, the study aims to speed right-ventricular assessment in suspected ...

The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...

With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.

Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under ...

Boston Scientific’s $374/share Penumbra deal boosts mechanical thrombectomy exposure and growth. Click here to learn more ...

The proportion of patients with postoperative pulmonary complications in the first 5 days after thoracic surgery did not ...

Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes ...

Age-adjusted D-dimer cutoffs can safely rule out deep vein thrombosis (DVT) in many suspected cases, according to the ...